title: High-dose FOLFIRI, surgery, and radiofrequency ablation for patients with unresectable liver metastases from colorectal cancer.
abstract: BACKGROUND
  To evaluate a strategy combining high-dose 5FU-irinotecan-leucovorin (HD-FOLFIRI) chemotherapy, radiofrequency ablation and surgery in patients with unresectable liver metastases from colorectal cancer.
  
  
  METHODS
  Patients, all presenting UDP glucuronosyl transferase-1A1 (UGT1A1) 6/6 or 6/7 genotype, received HD-FOLFIRI (with high-dose irinotecan: 260 mg/m(2)), one cycle every two weeks. The feasibility of local therapy (surgery and/or radiofrequency) was assessed every four cycles. The objective of therapy was the complete clearance rate of metastases.
  
  
  RESULTS
  The trial was terminated after inclusion of 18 out of the 40 planned patients due to insufficient recruitment. The median number of metastases was seven (range=2-30). On intention-to-treat analysis, six patients (33.3%) received local treatment of metastases with complete clearance of metastases in each case. Median progression-free and overall survivals were 15.3 months and 33.7 months, respectively.
  
  
  CONCLUSIONS
  The assessed strategy is feasible and allows for a complete clearance of metastases in one third of patients, with prolonged survival.
authors.affiliation: University Hospital, University Nord de France, Lille, France. mohamed.hebbar@chru-lille.fr
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hebbar
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Truant
authors.forename: Christophe
authors.initials: C
authors.lastname: Desauw
authors.forename: Geraldine
authors.initials: G
authors.lastname: Sergent-Baudson
authors.forename: Stephane
authors.initials: S
authors.lastname: Cattan
authors.forename: Guillaume
authors.initials: G
authors.lastname: Piessen
authors.forename: François-Rene
authors.initials: FR
authors.lastname: Pruvot
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017115:Catheter Ablation; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005838:Genotype; D014453:Glucuronosyltransferase / Q000235:genetics; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult; D000099148:UGT1A1 Enzyme
chemical_list: D002166:Camptothecin; D005472:Fluorouracil; D014453:Glucuronosyltransferase; D002955:Leucovorin; D000099148:UGT1A1 Enzyme